Revance Therapeutics Statistics
Total Valuation
CLRB has a market cap or net worth of $13.49 million. The enterprise value is $54,395.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, before market open.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLRB has 2.86 million shares outstanding. The number of shares has increased by 143.72% in one year.
| Current Share Class | 2.86M |
| Shares Outstanding | 2.86M |
| Shares Change (YoY) | +143.72% |
| Shares Change (QoQ) | +9.87% |
| Owned by Insiders (%) | 1.79% |
| Owned by Institutions (%) | 7.87% |
| Float | 2.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.94 |
| P/TBV Ratio | 1.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.47 |
| Quick Ratio | 2.31 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -208.72% and return on invested capital (ROIC) is -235.20%.
| Return on Equity (ROE) | -208.72% |
| Return on Assets (ROA) | -97.91% |
| Return on Invested Capital (ROIC) | -235.20% |
| Return on Capital Employed (ROCE) | -460.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.23M |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLRB has paid $66,000 in taxes.
| Income Tax | 66,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.68% in the last 52 weeks. The beta is 0.42, so CLRB's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -92.68% |
| 50-Day Moving Average | 7.41 |
| 200-Day Moving Average | 17.92 |
| Relative Strength Index (RSI) | 36.86 |
| Average Volume (20 Days) | 121,263 |
Short Selling Information
The latest short interest is 66,900, so 2.34% of the outstanding shares have been sold short.
| Short Interest | 66,900 |
| Short Previous Month | 164,965 |
| Short % of Shares Out | 2.34% |
| Short % of Float | 2.38% |
| Short Ratio (days to cover) | 0.40 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -46.18M |
| Pretax Income | -51.04M |
| Net Income | -24.54M |
| EBITDA | -45.92M |
| EBIT | -46.18M |
| Earnings Per Share (EPS) | -$23.40 |
Full Income StatementBalance Sheet
The company has $13.91 million in cash and $474,349 in debt, giving a net cash position of $13.43 million or $4.70 per share.
| Cash & Cash Equivalents | 13.91M |
| Total Debt | 474,349 |
| Net Cash | 13.43M |
| Net Cash Per Share | $4.70 |
| Equity (Book Value) | 9.64M |
| Book Value Per Share | 5.03 |
| Working Capital | 8.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$43.60 million and capital expenditures -$82,562, giving a free cash flow of -$43.69 million.
| Operating Cash Flow | -43.60M |
| Capital Expenditures | -82,562 |
| Free Cash Flow | -43.69M |
| FCF Per Share | -$15.29 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
